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Abstract
Background: Metformin protection against cancer risk in Orientals is uncertain. We examined the possible
metformin effect on total, esophageal, gastric, colorectal (CRC), hepatocellular (HCC) and pancreatic cancers in a
Taiwanese cohort.
Methods: A representative sample of 800,000 was drawn from the Taiwanese National Health Insurance data of
2000. A cohort of 480,984 participants 20 years or older, diabetes-cancer-free on 1st January 2000 was formed and
categorized as four groups by DM and metformin usage status. Eligible incident cancer events had to occur one
year after the index date until the end of 2007. The Cox proportional-hazards model evaluated relative risk of
cancer for treated DM patients with or without metformin. The covariates included age, gender, other oral anti-
hyperglycemic medication, Charlson comorbidity index (CCI) score and metformin exposure dosage and duration.
Results: With diabetes but no anti-hyperglycemic medication, cancer incidence density increased at least 2-fold for
total, CRC and HCC. On metformin, total, CRC and HCC incidences decreased to near non-diabetic levels but to
varying degrees depending on gender and cancer type (CRC in women, liver in men). Adjustment for other oral
anti-hyperglycemic agents usage and CCI made the benefit of metformin more evident [hazard ratios (95%
confidence intervals): total 0.12 (0.08-0.19), CRC 0.36 (0.13-0.98), liver 0.06 (0.02-0.16), pancreas 0.15 (0.03-0.79)]. There
was a significant gender interaction with metformin in CRC which favored women. Metformin dosage for a
significant decrease in cancer incidence was ≤500 mg/day.
Conclusions: Metformin can reduce the incidences of several gastroenterological cancers in treated diabetes.
Background
Diabetes (DM) is a significant risk factor for total cancer
incidence and mortality [1-3] and for some site-specific
cancers, notably breast and colorectal (CRC) [4,5], and
probably endometrial, prostate, and pancreas [6-8]. These
cancers have possible underlying mechanisms to do
with energy throughput and balance, hyperinsulinemia or
insulin resistance, or other hormone sensitivity [9].
Such findings may be relevant even before DM is clinically
manifest or biochemical criteria are met, which is to say
with pre-DM or the metabolic syndrome.
Diabetes treatment might affect cancer incidence and
mortality [8-13]. Since the 1960s, metformin (one of the
biguanides) has become the first line anti-hyperglycemic
agent in type 2 diabetes (T2DM) treatment worldwide
[14]. It has been shown to be potentially cancer protec-
tive in a pilot study on incidence in Scotland [15], in a
later cohort study [16] and, indirectly, in an administrative
population-based study on mortality in Saskatchewan,
Canada [17].
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also provides evidence that CRC may be prevented by
metformin; a retrospective cohort study of UK databases
showed this for colorectal and pancreatic cancers [18];
and hospital-based case-control studies suggest this is so
for hepatocellular in Italy [19] and pancreatic cancers in
the US [7,8].
No information is available about these possibilities
with regard to non-Caucasian ethnicity, especially where
both T2DM prevalence is increasing and cancer patterns
changing towards those in advanced economies, as in
the Asia Pacific region [20-22]. Yet, there is little known
about site-specific cancer in relation to metformin usage
pattern (i.e., duration and dosage). Because the gastroen-
terological cancer cluster is the major cause of cancer in
Taiwan [23], we used representative National Health
Insurance (NHI) datasets for Taiwan to form a cohort
to assess total and gastroenterological (esophagus, sto-
mach, CRC, liver and pancreas) cancers incidences in
relation to metformin usage among T2DM.
Methods
Data sources
Taiwan launched a single-payer NHI Program in 1995.
As of 2007, 98.4% of Taiwan’s 22.96 million population
was enrolled in this program. The NHI Research Data-
base (NHIRD) derived from this system, subject to a
double scrambling protocol is provided for research pur-
poses. Based on the registration files and original claims
data for reimbursement in the NHIRD, specific data
subsets are constructed [24].
Cohort formation
The Longitudinal Health Insurance Database 2000
(LHID2000) contains all the original claims data of
800,000 beneficiaries, randomly sampled from the year
2000 Registry for Beneficiaries of the NHIRD [24].
There are no significant differences in the gender or age
distributions or in the average insured payroll-related
amounts between the patients in the LHID2000 and the
original NHIRD. We have studied the LHID2000 with
antecedent data from 1st January 1996, which allowed
us to exclude people with prevalent DM during the per-
iod to 31st December 1999. To obtain incident T2DM
subjects, we formed a cohort of 480,984 participants
who were 20 years or older and were DM and cancer
free on 1st January 2000 and non-use of DM medication
from 1996-1999. The research was approved by the
Institutional Review Board of the NHRI.
Measurements
T2DM ascertainment, grouping and index date
T2DM patients were defined as those who had at least two
DM records (A181, pre-ICD before 2000, or ICD-250)
within one year during 2000-2007, followed up for at least
six months, and had no insulin at any time except for brief
usage during a hospital admission.
We categorized all cohort subjects into four groups.
The first was the T2DM patients who used metformin
(n = 12,005) during 2000-2007 with at least two pre-
scriptions. The second was the T2DM patients who did
not use metformin (n = 4,597) but had oral DM medica-
tions except metformin, defined in the same way as
metformin users. The third was the T2DM patients who
did not use any oral anti-hyperglycemic medication (n =
8,643). The last was those subjects without any diagnosis
of DM or use of DM medications during 2000-2007
(n = 417,844).
The index date for a randomly-selected non-DM, cor-
responded to that of a metformin user, with the same
gender-and-age (born in the same year and month).
Those selected were required to have been followed for
at least 6 months and cancer-free during the first year
after their index date in the same way as their metfor-
min user counterpart. To summarize, the index date
was the date of first prescription of metformin (metfor-
min users), that for the first prescription of any other
oral medications (non-metformin users), that of first
diagnosis of DM (DM without medication) or the
assigned date for the non-DM group. Due to different
index date assignments of those DM patients who did
not have medication, we limited the consideration of
any effect of metformin use to those who had oral anti-
hyperglycemic medications.
Metformin usage
Mean metformin dose was the cumulative dosage of all
metformin prescriptions to the event or censored date
divided by the cumulative duration from the index date
to the last metformin prescription before event or cen-
sored date or the end of 2007. Mean metformin dosage
was expressed in daily 500 mg units. We treated ‘dura-
tion’ as a time-dependent variable in modeling to avoid
immortal time bias [25].
Cancer event ascertainment and cancer incidence density
To consider an exposure (metformin) and outcome
(cancer) relationship, incident cancer (A08-A14/
ICD140-208) cases were only valid if they occurred at
least one year after the index date until 31st December
2007. We only considered the first cancer in the second
year or beyond and when cancer diagnosis was recorded
a second time within any year. To be cancer free, there
was no record of cancer at anytime after the index date.
Otherwise, cancer status was regarded as uncertain and
the subject deleted from the study. Cancers studied
were those at 5 specific gastrointestinal sites were
esophagus (150/A090), gastric (151/A091), CRC (153-
154/A093-A094), hepatic (155/A095) and pancreatic
(157/A096).
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number of incident cancer events divided by 10,000 per-
son-years at risk followed (years after the index date
until the first cancer diagnosis before the end of 2007
or, for non-cancer subjects, date of withdrawal from
NHI or the end of 2007). For comparison, we used the
age-gender-adjusted incidence rates calculated from the
2007 National Cancer Registry in Taiwan.
Covariates
Comorbidity was measured by the Charlson comorbidity
index (CCI) [26] using the diagnoses recorded in the
NHI before the index date. This did not include the
diagnosis of DM because subjects were DM-free before
the index date. Use of any other oral anti-hyperglycemic
agents (sulfonylureas, meglitinides, glitazones, and an
alpha-glucosidase inhibitor) was recorded as ‘yes’ or ‘no’.
Other covariates included age (20-49, 50-59, 60-69, ≥70
yrs), gender and geographical region.
Statistical analysis
The differences among four groups were evaluated by
ANOVA (CCI score) and by chi-square (demographics).
For the comparison of metformin users with those who
had oral anti-hyperglycemic medications except metfor-
min for total and 5 site-specific cancers, the hazard
ratios (HRs) for cancer incidence were estimated by Cox
proportional-hazards models. In these models, the time
variable was the interval between the index date and the
date of cancer ascertainment, or date of withdrawal
from NHI, or December 31, 2007. The potential covari-
ates included age, gender, other oral anti-hyperglycemic
medication usage, CCI score and dose and duration of
metformin exposure. Furthermore, gender-specific mod-
els were also evaluated for total and site-specific cancers.
The proportional hazards assumption was evaluated by
comparing estimated log-log survival curves for all cov-
ariates. The log-log survival plots, stratified by metfor-
min usage status, of all models graphically showed two
parallel lines, indicating no violation of the assumption.
The statistics software SAS 9.1 was used for data man-
agement and modeling.
Results
Since the non-DM subjects were sampled by matching to
DM patients with metformin, the two groups have similar
age, gender and geographical distribution. The majority
were over 50 years old and males. More than 40% of the
subjects lived in northern Taiwan and less than 5% lived
in eastern Taiwan and off-shore isles. More females were
in the DM without medication group (51.4%) than the
others (45.1%-46.0%). The CCI median for the non-DM
group indicates that more than half of them have no
comorbidity with a mean of 0.25, but, for the DM groups,
half experience 4 comorbidities or more. The follow-up
time for four groups ranged between 0.5-7.99 years. The
diabetes without metformin group had the shortest mean
follow-up time (3.52 years) among groups. Around 2%
DM patients withdrew from NHI, while this was more
than 4% for the non-DM. For those who were metformin
users, 30% subjects used ≤500 mg/day, half used metfor-
min for more than 2 years. (Table 1)
Total and site-specific CIDs per 10000 person-years
and 95% confidence intervals (CIs), as well as age-
gender-standardized Taiwanese population cancer inci-
dences, are listed in Table 2. Except for pancreatic cancer,
both total and site-specific cancer standardized incidences
are equivalent to the CIDs in our cohort. The total CID is
46.0 for non-DM subjects, 97.6 for DM patients without
medication, 91.7 for DM patients without metformin and
44.8 for DM patients with metformin. Similar patterns
were found regardless of gender.
For site-specific cancers, only CRC and liver cancer
reveal significant differences among groups, which seem
related to gender. For women, non-metformin using DM
patients have three times the CRC CID of people without
DM (22.6 vs. 7.4). Yet, compared to non-metformin
users, users have only one-sixth of their counterparts’
incidence (3.52 vs. 22.6). For liver cancer, it is only the
difference in men among groups which achieves signifi-
cance. The incidence rate for males, who have DM and
do not use metformin (29.1) is three times and twice that
of men without DM (8.6) and that of men with DM who
use metformin (12.5), respectively.
The metformin users were less likely to develop all-type
cancers, CRC and liver cancer (model 1, HRs, 0.47, 0.38
and 0.53, P < 0.01) than non-metformin users (Table 3).
When adjusted for age, gender, CCI score and time-
dependent duration of metformin use (Model 2), great
reductions in cancer risk for metformin users are seen
for total cancer, esophageal, liver, and pancreatic cancer
(HRs, 0.13, 0.44, 0.06, and 0.15, respectively) though eso-
phageal and CRC are not significant. With additional
adjustment for use of other anti-hyperglycemic medica-
tion, the HR of metformin users to non-metformin users
did not change substantially (Model 3). However, for
CRC, the risk when metformin is used is smaller and sig-
nificant (HR, 0.36, P < 0.05). No significant gender and
metformin use interaction was found for total cancer and
site-specific cancers except CRC (data not shown).
Metformin users were categorized into three groups
by average daily doses compared to DM patients who
use other oral medication by gender (Figures 1 and 2).
Gender differences are apparent in CRC and liver can-
cer. In general, female metformin users are at a signifi-
cantly lower risk of CRC for all three dosages compare
to non-users (HRs, 0.05-0.17) while male users are
not (HRs, 0.77-1.01). By contrast, there is an extremely
low risk of liver cancer for male metformin users
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lower risk for females (HRs, 0.28-0.44) (data not shown).
Cancer risk was significantly decreased with metformin,
the dose can be as little as ≤500 mg per day, which may
represent a threshold effect.
Discussion
Among cancer free individuals, we found that total and
all 5 site-specific gastroenterological cancer incidences
increased with T2DM, although this was only significant
for total, CRC and liver cancers. With metformin treat-
ment, incident total cancer was reduced to near or
below non-DM incidence. This was seen for both gen-
ders and at the lowest usual dose of metformin used in
clinical practice (≤500 mg/day). This is unlikely to be
due only to DM severity, because the dose-response is
almost a plateau with higher doses, an indication of DM
severity. In the case of CRC, the metformin-treated
women have less cancer risk than the non-DM popula-
tion. However, the interaction between gender and CRC
Table 1 Characteristics of study subjects by diabetes and metformin using status
Descriptor Non-DM
†
(n = 10491)
DM without medication
‡
(n = 8130)
DM without metformin
§
(n = 4327)
DM with metformin¶
(n = 11390)
P-value
Age, n (%) <0.001
20-49 yr 2685 (25.6) 2230 (27.4) 1067 (24.7) 2977 (26.1)
50-59 yr 3483 (33.2) 2202 (27.1) 1156 (26.7) 3638 (31.9)
60-69 yr 2406 (22.9) 1639 (20.2) 940 (21.7) 2530 (22.2)
≥70 yr 1917 (18.3) 2059 (25.3) 1164 (26.9) 2245 (19.7)
Female gender, n (%) 4822 (46.0) 4177 (51.4) 1966 (45.4) 5134 (45.1) <0.001
Geographical area, n (%) <0.001
North 4938 (47.1) 4145 (51.0) 1731 (40.0) 5031 (44.2)
Central 2472 (23.6) 1739 (21.4) 1052 (24.3) 2638 (23.2)
South 2761 (26.3) 2032 (25.0) 1359 (31.4) 3285 (28.8)
East 250 (2.38) 150 (1.85) 138 (3.19) 357 (3.13)
Off-shore 70 (0.67) 64 (0.79) 47 (1.09) 79 (0.69)
Charlson comorbidity index score <0.001
Mean ± SD 0.25 ± 1.28 5.29 ± 3.68 4.79 ± 3.77 4.38 ± 3.54
Median ± IQR 0.00 ± 0.00 5.00 ± 6.00 4.00 ± 5.00 4.00 ± 6.00
Min-Max 0-15 0-17 0-21 0-20
Follow-up time (yr)
Mean ± SD 3.94 ± 2.09 3.94 ± 2.14 3.52 ± 2.10 3.90 ± 2.08
Median ± IQR 3.80 ± 3.49 3.80 ± 3.65 3.28 ± 3.47 3.76 ± 3.44
Min-Max 0.50-7.99 0.50-7.99 0.50-7.99 0.50-7.99
Withdrawal from NHI, n (%) 451 (4.30) 157 (1.93) 88 (2.03) 240 (2.11)
Mean daily metformin dose, n (%)
≤500 mg 3460 (30.4)
500-1000 mg 4012 (35.2)
≥1000 mg 3918 (34.4)
Metformin use duration (day)
Mean ± SD 931 ± 765
Median ± IQR 755 ± 1200
Min-Max 1-2911
† Insured who had no diabetes (DM) and had not used diabetes medication during 1996-2007.
‡ Newly diagnosed DM patients who never used any DM medication during 2000-2007.
§ Newly diagnosed DM patients who never used insulin or metformin during 2000-2007.
¶ Newly diagnosed metformin-treated patients who never used insulin during 2000-2007.
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tion of the findings for women to men. The same is not
the case for gender and hepatocellular cancer (HCC),
where, if women experience the higher incidence seen
in men, they may benefit from metformin protection.
A shared pathogenesis for DM and certain cancers is
possible, e.g., in beta oxidation of fatty acids or mito-
chondrial function. The prevention or management of
the one might lead to corresponding outcomes for the
other, as seems to be the case for metformin [8,12].
Metformin might protect against tumorigenesis through
several mechanisms [8,10,11]. Metformin stimulates per-
ipheral AMP-activated protein kinase (AMPK) with
reduced hepatic gluconeogenesis, increased hepatic fatty
acid oxidation and insulin sensitivity in muscle. In phy-
siological circumstances, AMPK acts as an intracellular
fuel sensor and is activated when the cellular AMP/ATP
ratio increases. It is of interest to those cancers for
which energy imbalance is a risk factor [22]. Dependent
on cellular p53 and cyclin status, tumor cell cycle and
growth is impaired by metformin. Metformin may
counter age-related metabolic phenomena, such as sar-
copenia, increased body fat and osteopenia, insulin sen-
sitivity and adipokines. In our study, we have considered
the role of age to any effect of metformin on the DM-
cancer nexus; adjustment for age makes no discernable
difference to the findings. Since the mechanism is likely
to be through regulation of cellular energy metabolism,
this has implications for measures designed to enhance
energy expenditure by physical activity and avoid excess
energy intake as well.
Severity and duration of DM is likely to be important
for the effectiveness of metformin. In this administrative
cohort, we do not have a direct measure of DM severity
like glycated hemoglobin or of BMI. In Taiwan, the usual
first line oral anti-hyperglycemic therapeutic agents for
T2DM are sulfonylureas and biguanides (metformin). It
can be inferred that, where DM is more difficult to con-
trol, the dose of one or both of these classes of oral anti-
hyperglycemic agents will be increased. On the other
hand, other anti-hyperglycemic agents may mask or miti-
gate against some of this metformin-dependent cancer
Table 2 Cancer incidence density by diabetes and metformin using status
Cancer type
† Taiwanese population Incidence
‡ Incidence density (95%CI) of study cohort (per 10,000 person-years)
Non DM
(n = 10491)
DM without medication
(n = 8130)
DM without metformin
(n = 4327)
DM with metformin
(n = 11390)
Total cancer 49.9 46.0 (39.5-52.6)
ab 97.6 (86.9-108)
ac 91.7 (76.6-107)
bd 44.8 (38.6-51.0)
cd
Male 59.3 50.3 (41.0-59.6)
ab 122 (104-139)
ac 107 (84.9-130)
bd 47.7 (39.0-56.4)
cd
Female 41.2 41.0 (31.9-50.1)
ab 75.7 (62.6-88.8)
ac 74.0 (54.1-93.8)
bd 41.2 (32.4-50.1)
cd
Esophagus 1.14 2.94 (1.28-4.60) 5.14 (2.62-7.66) 4.03 (0.81-7.26) 4.78 (2.74-6.83)
Male 2.09 3.63 (1.11-6.15) 7.45 (3.05-11.9) 5.09 (0.10-10.1) 5.83 (2.78-8.89)
Female 0.20 2.13 (0.04-4.21) 3.05 (0.38-5.73) 2.84 (-1.10-6.78) 3.52 (0.91-6.13)
Stomach 2.64 3.91 (1.99-5.83) 5.14 (2.62-7.66) 6.71 (2.55-10.9) 5.46 (3.28-7.65)
Male 3.49 3.63 (1.12-6.15) 6.78 (2.58-11.0) 8.90 (2.31-15.5) 4.58 (1.88-7.29)
female 1.86 4.23 (1.30-7.17) 3.67 (0.73-6.60) 4.26 (-0.56-9.09) 6.53 (2.98-10.1)
Colorectal 7.31 7.07 (4.50-9.64)
ab 19.8 (14.9-24.8)
ac 17.4 (10.7-24.1)
bd 6.83 (4.39-9.27)
cd
Male 8.63 6.78 (3.35-10.2)
a 23.6 (15.8-31.4)
ab 12.7 (4.83-20.6) 9.57 (5.66-13.5)
b
female 6.06 7.40 (3.53-11.3)
a 16.4 (10.2-22.6)
b 22.6 (11.6-33.7)
ac 3.52 (0.91-6.12)
bc
Liver 6.55 5.88 (3.53-8.23)
ab 24.3 (18.8-29.7)
ac 18.7 (11.8-25.7)
b 10.2 (7.24-13.2)
c
Male 9.25 8.64 (4.76-12.5)
ab 32.3 (23.2-41.4)
ac 29.1 (17.2-41.0)
bd 12.5 (8.01-16.9)
cd
Female 3.90 2.65 (0.33-4.98)
a 17.0 (10.7-23.3)
a 7.10 (0.88-13.3) 7.54 (3.72-11.3)
Pancreas 0.99 2.45 (0.93-3.96) 5.14 (2.62-7.66) 4.70 (1.22-8.18) 4.78 (2.74-6.83)
Male 1.17 2.72 (0.54-4.90) 5.42 (1.67-9.18) 5.09 (0.10-10.1) 5.41 (2.47-8.36)
female 0.81 2.13 (0.04-4.21) 4.88 (1.50-8.27) 4.26 (-0.56-9.09) 4.02 (1.24-6.81)
† ICD-9-CM also incorporates the A-code for cancer which was used in Taiwan in ambulatory care settings before the year 2000. Total cancer (140-208/A08-A14),
esophagus cancer (150/A090), stomach cancer (151/A091), colorectal cancer (153-154/A093-A094), liver cancer (155/A095), pancreas cancer (157/A096).
‡ Age-gender-standardized cancer incidence per 10,000 persons (95% confidence intervals) in the Taiwanese Cancer Registry Annual Report for 2007.
a, b, c, d: Statistical significance was estimated by using the overlap rule for 95% CIs. Where there is the same superscript it means that there is significant
difference between the two groups.
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cerns about sulfonylureas [17] which may increase the
risk of cancer in DM. We, therefore, considered dose and
found it unlikely that increasing severity and its correc-
tion was the sole explanation for our findings. However,
the finding that total and CRC CIDs may drop below
that in the non-DM may still be attributed in part to the
presence of unrecognized pre-DM. We also adjusted for
other oral agent usage and found that this decreased the
HR even further in the metformin users.
Since there are possible comorbidities which may
modify the relation between DM, metformin and cancer,
we further adjusted for CCI score in the analyses. The
results were even more convincing after these adjust-
ments and suggest that the comorbidities seen with DM
may themselves be important in increasing cancer risk.
The most likely candidate disease mechanism, common
to most comorbidities, including obesity, would be
inflammation which is one of the bases for cancer [21].
The CCI adjustment would have allowed for the more
complete effect of metformin to be revealed.
A potential selection bias in this study comes from the
prescription of metformin. On the one hand, those who
were prescribed metformin might have been more likely
to be obese, one of the well recognized cancer risks. So,
the cancer protection effect of metformin illustrated in
this study would be underestimated. On the other hand,
those taking metformin might also have had their renal
function better preserved (serum creatinine <1.5 mg/
dL), which would have led to an underestimation of
cancer risk incurred through severe kidney disease and
an overestimation of metformin effect. Other DM treat-
ment than oral agents could also affect risk of cancer in
DM. In our study, the CIDs for total and site-specific
cancers of those with DM but without medication were
similar to those with DM but without metformin. We
excluded patients who ever used insulin except briefly
during a hospital admission. Sulfonylureas may increase
risk of cancer [17], and we controlled for any other oral
anti-hyperglycemic agents ever used before diagnosis of
cancer.
Our findings are referable to the entire Taiwanese
population and provided sufficient power to detect a
metformin effect at several sites. The second Scottish
study detected a favorable reduction in unadjusted CRC,
breast and lung cancer incidences, and a significant
adjusted CRC incidence, with metformin [15,16] in a
population at high risk. Likewise, the Taiwanese popula-
tion has a relatively high incidence of HCC and we
report the first evidence to our knowledge that metfor-
min use is linked to its reduction in the DM population.
In the case of CRC, our report supports that of Libby
Table 3 Hazard ratios in metformin-treated type 2 diabetes for cancer incidence
Cancer type cancer cases/total ID
† Model 1
‡
HR (95%CI)
Model 2
§
HR (95%CI)
Model 3
¶
HR (95%CI)
Total cancer
Comparator
†† 140/4327 91.7 ref. ref. ref.
Metformin users 199/11390 44.8 0.47 (0.38-0.59)*** 0.50 (0.40-0.62)*** 0.12 (0.08-0.19)***
Esophagus cancer
Comparator
†† 6/4193 4.03 ref. ref. ref.
Metformin users 21/11212 4.78 1.15 (0.46-2.84) 1.27 (0.51-3.16) 0.44 (0.07-2.61)
Stomach cancer
Comparator
†† 10/4197 6.71 ref. ref. ref.
Metformin users 24/11215 5.46 0.78 (0.37-1.63) 0.86 (0.41-1.81) 1.41 (0.42-4.73)
Colorectal cancer
Comparator
†† 26/4213 17.4 ref. ref. ref.
Metformin users 30/11221 6.83 0.38 (0.23-0.65)*** 0.42 (0.25-0.71)** 0.36 (0.13-0.98)*
Liver cancer
Comparator
†† 28/4215 18.7 ref. ref. ref.
Metformin users 45/11236 10.2 0.53 (0.33-0.85)** 0.54 (0.34-0.87)* 0.06 (0.02-0.16)***
Pancreas cancer
Comparator
†† 7/4194 4.70 ref. ref. ref.
Metformin users 21/11212 4.78 0.99 (0.42-2.33) 1.11 (0.47-2.62) 0.15 (0.03-0.79)*
†: Incidence density per 10,000 person-years.
‡: Unadjusted hazard ratio, HR, (95% confidence interval, 95% CI), by Cox regression.
§: Adjusted for age group, and gender.
¶: Adjusted for age group, gender, other oral anti-hyperglycemic medication, CCI score, and duration of metformin exposure which was treated as a time
dependent variable
††: Diabetes patients who had no metformin, but might have used any other oral anti-hyperglycemic medication.
*P < .05, **P < .01, ***P < .001
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for cancer incidence for men (n = 8,167). Adjusted for age
group, gender, other oral anti-hyperglycemic medication, CCI score,
and duration of metformin exposure (a time dependent variable).
Reference: Diabetes patients use oral anti-hyperglycemic medication
except metformin.
Figure 2 Hazard ratios in metformin-treated type 2 diabetes
for cancer incidence for women (n = 7,100). Adjusted for age
group, gender, other oral anti-hyperglycemic medication, CCI score,
and duration of metformin exposure (a time dependent variable).
Reference: Diabetes patients use oral anti-hyperglycemic medication
except metformin.
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women. Taiwan is experiencing increasing incidences of
breast cancer and CRC [27] towards rates seen in Eur-
opean populations which may extend its relevance
beyond Orientals.
We found a significant lower relative risk for pancrea-
tic cancer in metformin users as have previous observa-
tions [6,7]. However, the CID in diabetes was not
significantly different to that of non-DM. Li’s study [7]
which demonstrated potential pancreatic cancer protec-
tion by metformin, was hospital-based and case-control
in the US. Ours was a representative population-base
cohort of DM-cancer-free subjects at baseline. Our
study resolves some of the outstanding issues in the US
study in regard to generalizability and the possible con-
founding effects of other DM pharmacotherapy, other
diseases and their treatment. However, ours is princi-
pally an oriental and Li’s a mainly white population so
that cross-ethnic robustness remains to be elucidated.
Metformin might operate to prevent or check tumori-
genesis through a basic underlying mechanism and dis-
order, with generalizability. It may help sort out the
pathogenetic, preventive and management differences
for site-specific cancers. With incidence, the endpoint of
our study, when a subject develops a cancer, this can be
considered in relation to the oral anti-hyperglycemic
agent used to that point and need not be confused by
changes in medication subsequent to the diagnosis.
There are gender differences in the development of
body fat distribution with relatively earlier and greater
abdominal fatness (and fatty liver) in men [28] and in
the protective role of estrogen against insulin resistance
[29-33]. We found gender differences in the effect of
metformin against CRC and HCC. While the prevalence
of HCC and CRC is greater in men, women lose some
protection against CRC after the menopause [34,35].
Where there has been a decline in CRC incidence in
Canada, it has been mainly in women [36]. In Taiwan,
hepatitis B and C with aflatoxin exposure is a more
likely cause of cirrhosis and HCC than alcohol excess,
although alcohol may be a contributor to the gender dif-
ference [27] and abdominal obesity through non-alco-
holic steatohepatitis with cirrhosis may play a role.
Gender disparity in HCC may be due to differences in
MyD88-dependent IL-6 production [37]. Hepatic estro-
gen receptor status may also affect the progression of
HCC [38]. In our study for CRC, metformin users were
older than the others (data not shown), a somewhat
elderly estrogen-deficient group. Nevertheless, insulin
resistance is related to estrogen deficiency and/or andro-
gen excess as evidenced in the polycystic ovarian syn-
drome and this is responsive to metformin [39,40].
Therefore, metformin might act differentially and
favorably on estrogen-deficient women. The opposite
may be the case in men where there is a gender differ-
ence in susceptibility to HCCa l o n gw i t ha l t e r e de s t r o -
gen metabolism and insulin resistance in cirrhosis [41].
The present study has several limitations. Firstly, we
have required that for an eligible event to be counted it
had to be diagnosed one year after metformin com-
menced. Consequently, for DM subjects and their non-
exposure counterparts in the last year (2007), there
would have been no chance to count their cancer out-
come. Secondly, obesity is a risk factor for DM and can-
cer and should be considered as a confounder. However,
this administrative dataset does not have systematic clin-
ical measurements available for BMI or obesity. Body
weight could differ in patients treated with different
anti-DM drugs. This could lead to an underestimation
of the true effect of metformin (the use of sulphonylour-
eas and gliazones is associated with weight gain and
metformin with weight loss). While BMI data are not
available, we can presume that the adverse outcomes of
BMI outside acceptable limits will be manifest to some
extent, in comorbidities. These we have taken into
account in the CCI adjustment. Thirdly, for some can-
cers studied, the events were few and did not allow us
to judge whether metformin is protective or not.
Fourthly, we do not have direct linkage of the NHI data-
base to death certificates. If a subject leaves the cohort,
that death or migration is the likely reason. There were
no differences in the disappearance rates among the
three DM groups which might have led to erroneous
interpretations of our data. In addition, there are caveats
about populations to whiche x t r a p o l a t i o n sf r o mo u r
findings may be made. The population studied is domi-
nantly Orientals. The problem of DM and its sequelae is
nevertheless similar to that in Europeans [15-18]. At
least for North East Asia, where living and eating pat-
terns are similar, our large population findings should
be relevant.
Metformin may reduce cancer risk and randomized-
trials should be conducted. Our study provides evidence
to encourage evaluation of the risk of cancer in DM
patients. This is because the cohort evidence of DM
antedating major cancers like those of breast and CRC,
along with experimental, points to cause and effect.
Moreover, our study shows that low dose metformin
can prevent certain common cancers (CRC and HCC)
and probably certain less common cancers (pancreas)
for Taiwanese. Metformin has few adverse side effects;
including that of lactic acidosis [42]. The gastrointestinal
side effects are manageable if starting dose is low. Cau-
tion is required about effects on vitamin B-12 and
homocysteine status and more work is required in large
population studies to evaluate this [43].
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Low dose metformin is protective against total cancer
and several cancers, including CRC in women, HCC in
men and pancreatic for treated DM patients. This is evi-
dent in a population with an increasing prevalence of
DM and at increasing risk of cancer profiles characteris-
tic of economic development. Cancer prevention may be
enhanced by avoiding DM or by its control with metfor-
min. Since metformin would seem to act through cellu-
lar energy regulation, diet and exercise operate to
reduce cancer risk in a similar way, although gender dif-
ferences indicate that ancillary mechanisms and preven-
tive and management approaches may be possible.
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